Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 509-523

  Abdallah, Chadi G ^a,b   Sanacora, Gerard ^a,c   Duman, Ronald S ^a,b,c   Krystal, John H ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c Yale University School of Medicine   (United States)

Author keywords

BDNF; biomarker; depression; mTOR; synaptic plasticity

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; AMINO ACID RECEPTOR BLOCKING AGENT;

ANTIDEPRESSANT ACTIVITY; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HOMEOSTASIS; HUMAN; MOOD DISORDER; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NEUROBIOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SYNAPTOGENESIS; TREATMENT RESISTANT DEPRESSION; BRAIN; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; METABOLISM; MOOD DISORDERS;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; KETAMINE; MOOD DISORDERS; NEURONAL PLASTICITY; PREFRONTAL CORTEX;

EID: 84921341863     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-053013-062946     Document Type: Article

References (99)

1. Collins PY, Patel V, Joestl SS, et al. 2011. Grand challenges in global mental health. Nature 475:27-30
2. Kessler RC, Berglund P, Demler O, et al. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62:593-602
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. Acute and longer-Term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am. J. Psychiatry 163:1905-17
4. Katz MM, Tekell JL, Bowden CL, et al. 2004. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566-79
5. Berman RM, Cappiello A, Anand A, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47:351-54
6. Murrough JW, Iosifescu DV, Chang LC, et al. 2013. Antidepressant efficacy of ketamine in treatmentresistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170:1134-42
7. Zarate CA Jr, Singh JB, Carlson PJ, et al. 2006. A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63:856-64
8. Diazgranados N, Ibrahim L, Brutsche NE, et al. 2010. A randomized add-on trial of an N-methyl-Daspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67:793-802
9. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. 2011. Rapid decrease in depressive symptoms with an N-methyl-D-Aspartate antagonist in ECT-resistantmajor depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:1155-59
10. Krystal JH, Karper LP, Seibyl JP, et al. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51:199-214
11. Domino EF, Chodoff P, Corssen G. 1965. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther. 6:279-91
12. Krystal JH, Petrakis IL, Limoncelli D, et al. 2003. AlteredNMDAglutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 28:2020-28
13. Skolnick P, Layer RT, Popik P, et al. 1996. Adaptation of N-methyl-D-Aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23-26
14. Mion G, Villevieille T. 2013. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci. Ther. 19:370-80
15. Valentine GW, Mason GF, Gomez R, et al. 2011. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res. 191:122-27
16. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71:939-46
17. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. 2012. Ketamine for depression: Where do we go from here?. Biol. Psychiatry 72:537-47
18. Blier P, ZigmanD, Blier J. 2012. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol. Psychiatry 72:e11-12
19. Szymkowicz SM, Finnegan N, Dale RM. 2013. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J. Affect Disord. 147:416-20
20. Murrough JW, Perez AM, Pillemer S, et al. 2013. Rapid and longer-Term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74:250-56
21. Diamond PR, Farmery AD, Atkinson S, et al. 2014. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J. Psychopharmacol. 28:536-44
22. Rasmussen KG, Lineberry TW, Galardy CW, et al. 2013. Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol. 27:444-50
23. Shiroma PR, Johns B, Kuskowski M, et al. 2014. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J. Affect Disord. 155:123-29
24. Segmiller F, Ruther T, Linhardt A, et al. 2013. Repeated S-ketamine infusions in therapy resistant depression: a case series. J. Clin. Pharmacol. 53:996-98
25. Larkin GL, Beautrais AL. 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 14:1127-31
26. Lapidus KA, Levitch CF, Perez AM, et al. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry 76:970-76
27. Chilukuri H, Reddy NP, Pathapati RM, et al. 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J. Psychol. Med. 36:71-76
28. Price RB, Iosifescu DV, Murrough JW, et al. 2014. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety 31:335-43
29. Price RB, Nock MK, Charney DS, Mathew SJ. 2009. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66:522-26
30. DiazGranados N, Ibrahim LA, Brutsche NE, et al. 2010. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71:1605-11
31. Thakurta RG, Das R, Bhattacharya AK, et al. 2012. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J. Psychol. Med. 34:170-75
32. Luckenbaugh DA, Ibrahim L, Brutsche N, et al. 2012. Family history of alcohol dependence and antidepressant response to an N-methyl-D-Aspartate antagonist in bipolar depression. Bipolar Disord. 14:880-87
33. Phelps LE, Brutsche N, Moral JR, et al. 2009. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-Aspartate antagonist. Biol. Psychiatry 65:181-84
34. Petrakis IL, Limoncelli D, Gueorguieva R, et al. 2004. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am. J. Psychiatry 161:1776-82
35. Citri A, Malenka RC. 2008. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33:18-41
36. Hardingham GE, BadingH. 2010. Synaptic versus extrasynapticNMDAreceptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11:682-96
37. TurrigianoG. 2012. Homeostatic synaptic plasticity: local and globalmechanisms for stabilizing neuronal function. Cold Spring Harb. Perspect. Biol. 4:a005736
38. Turrigiano G. 2011. Too many cooks?. Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu. Rev. Neurosci. 34:89-103
39. Beattie EC, Stellwagen D, Morishita W, et al. 2002. Control of synaptic strength by glial TNFalpha. Science 295:2282-85
40. Rutherford LC, Nelson SB, Turrigiano GG. 1998. BDNF has opposite effects on the quantal amplitude of pyramidal neuron and interneuron excitatory synapses. Neuron 21:521-30
41. Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59:1116-27
42. Dantzer R, O'Connor JC, Freund GG, et al. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9:46-56
43. Duman RS, Aghajanian GK. 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72
44. Popoli M, Yan Z, McEwen BS, Sanacora G. 2012. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13:22-37
45. Kang HJ, Voleti B, Hajszan T, et al. 2012. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18:1413-17
46. Bessa JM, Ferreira D, Melo I, et al. 2009. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol. Psychiatry 14:764-73
47. Yuen EY, Wei J, LiuW, et al. 2012. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73:962-77
48. Bessa JM, Morais M, Marques F, et al. 2013. Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens. Transl. Psychiatry 3:e266
49. Vyas A, Pillai AG, Chattarji S. 2004. Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior. Neuroscience 128:667-73
50. Krystal JH, Sanacora G, Duman RS. 2013. Rapid-Acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry 73:1133-41
51. Savitz J, Drevets WC. 2009. Bipolar and major depressive disorder: neuroimaging the developmentaldegenerative divide. Neurosci. Biobehav. Rev. 33:699-771
52. Ota KT, Liu RJ, Voleti B, et al. 2014. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat. Med. 20:531-35
53. Sen S, Duman R, Sanacora G. 2008. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-Analyses and implications. Biol. Psychiatry 64:527-32
54. Verhagen M, van der Meij A, van Deurzen PA, et al. 2010. Meta-Analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry 15:260-71
55. Autry AE, AdachiM, Nosyreva E, et al. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95
56. Li N, Lee B, Liu RJ, et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-64
57. Liu RJ, Lee FS, Li XY, et al. 2012. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71:996-1005
58. Li N, Liu RJ, Dwyer JM, et al. 2011. Glutamate N-methyl-D-Aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69:754-61
59. AbekawaT, Honda M, ItoK, KoyamaT. 2003. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology 169:247-56
60. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:2921-27
61. Moghaddam B, Adams BW. 1998. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-52
62. Lorrain DS, Baccei CS, Bristow LJ, et al. 2003. Effects of ketamine and N-methyl-D-Aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706
63. Bonaventure P, AluisioL, Shoblock J, et al. 2011. Pharmacological blockade of serotonin 5-HT(7) receptor reversesworking memory deficits in rats by normalizing cortical glutamate neurotransmission. PLOSONE 6:e20210
64. Lopez-Gil X, Babot Z, Amargos-Bosch M, et al. 2007. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32:2087-97
65. Chowdhury GM, Behar KL, Cho W, et al. 2012. 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol. Psychiatry 71:1022-25
66. Koike H, Iijima M, Chaki S. 2011. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 224:107-11
67. Maeng S, Zarate CA Jr, Du J, et al. 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63:349-52
68. Dwyer JM, Lepack AE, Duman RS. 2011. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int. J. Neuropsychopharmacology 15:429-34
69. Furey ML, Drevets WC. 2006. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 63:1121-29
70. Voleti B, Navarria A, Liu RJ, et al. 2013. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74:742-49
71. Salvadore G, Cornwell BR, Colon-Rosario V, et al. 2009. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 65:289-95
72. SalvadoreG, Cornwell BR, Sambataro F, et al. 2010. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415-22
73. Cornwell BR, Salvadore G, Furey M, et al. 2012. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 72:555-61
74. DuncanWC, Sarasso S, Ferrarelli F, et al. 2013. Concomitant BDNFand sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int. J. Neuropsychopharmacology 16:301-11
75. Salvadore G, van der Veen JW, Zhang Y, et al. 2011. An investigation of amino-Acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int. J. Neuropsychopharmacology 15:1063-72
76. Machado-Vieira R, Yuan P, Brutsche N, et al. 2009. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-Aspartate antagonist. J. Clin. Psychiatry 70:1662-66
77. Rybakowski JK, Permoda-Osip A, Skibinska M, et al. 2013. Single ketamine infusion in bipolar depression resistant to antidepressants: Are neurotrophins involved?. Hum. Psychopharmacol. 28:87-90
78. Haile CN, Murrough JW, Iosifescu DV, et al. 2014. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int. J. Neuropsychopharmacology 17:331-36
79. ZarateCAJr, BrutscheN, LajeG, et al. 2012. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry 72:331-38
80. Sos P, Klirova M, Novak T, et al. 2013. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol. Lett. 34:287-93
81. Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, et al. 2013. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 46:227-28
82. Anand A, Charney DS, Oren DA, et al. 2000. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-Aspartate receptor antagonists. Arch. Gen. Psychiatry 57:270-76
83. Deakin JF, Lees J, McKie S, et al. 2008. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 65:154-64
84. Krystal JH, Mathew SJ, D'Souza DC, et al. 2010. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 24:669-93
85. Krystal JH, Abi-SaabW, Perry E, et al. 2005. Preliminary evidence of attenuation of the disruptive effects of theNMDAglutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179:303-9
86. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. 2014. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J. Affect. Disord. 159:56-61
87. Hyder F, Rothman DL, Bennett MR. 2013. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc. Natl. Acad. Sci. USA 110:3549-54
88. Breier A, Malhotra AK, Pinals DA, et al. 1997. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry 154:805-11
89. Vollenweider FX, Leenders KL, Oye I, et al. 1997. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)-And (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur. Neuropsychopharmacology 7:25-38
90. Vollenweider FX, Leenders KL, Scharfetter C, et al. 1997. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacology 7:9-24
91. Rowland LM, Bustillo JR, Mullins PG, et al. 2005. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 162:394-96
92. Stone JM, Dietrich C, Edden R, et al. 2012. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 17:664-65
93. Taylor MJ, Tiangga ER, Ni Mhuircheartaigh R, Cowen P. 2011. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J. Psychopharmacol. 26:733-37
94. Yang S, Hu J, Kou Z, Yang Y. 2008. Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T. Magn. Reson. Med. 59:236-44
95. Morgan CJ, Curran HV, Independent Scientific Committee on Drugs. 2012. Ketamine use: a review. Addiction 107:27-38
96. Feder A, Parides MK, Murrough JW, et al. 2014. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71:681-88
97. Rodriguez CI, Kegeles LS, Levinson A, et al. 2013. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475-83
98. BlochMH, Wasylink S, Landeros-Weisenberger A, et al. 2012. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiatry 72:964-70
99. Dakwar E, Levin F, Foltin RW, et al. 2014. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol. Psychiatry 76:40-46